THQ, Inc. THQI
THQI was added to our watchlist as a possible bottom bounce-play. We have yet to see that bottom settle in. On Friday, the stock hit a new 52-wk low, but it appears as if it is still on the descent. The company has a PR out this morning:
AGOURA HILLS, Calif., Mar 05, 2012 (BUSINESS WIRE) — THQ Inc. (NASDAQ: THQI) today announced that THQ’s President and Chief Executive Officer Brian Farrell will make a presentation to investors at the Wedbush 2012 Technology, Media and Telecommunications: Management Access Conference on Wednesday, March 7, 2012, at 10:20 a.m. Eastern.
The presentation will be open to all interested investors through a live audio Web broadcast via the Internet on the Investor Relations Event Calendar page of THQ’s website located at http://investor.thq.com. An archived replay will also be available on the company’s website approximately 24 hours following the live broadcast.
EffTec International, Inc. EFFI
EFFI was added to our watchlist at midday on Feb. 28th as a momentum alert
At that time, the stock was trading around .13. What we saw next was a high of .181 the next morning, for a tidy 39% gain overnight!
Since then, the stock has consolidated to find a new level of support at our original alert price of .13, and we already know what this stock can do, so our eyes are open for more such bounce opportunities.
For those interested, a good place to start your DD here, would be with this EFFI investor presentation.
UnderSea Recovery Corporation UNDR
UNDR enjoyed a substantial momentum surge on Friday, trading sizable volume. It was observed bouncing off of a low of .0004, only to hit a high of .0009– That represents an intraday gain of over 100%.
As a result, Friday’s trading session saw abnormally high volume, and piqued our interest enough to warrant our paying of close attention this morning.
BioSante Pharmaceuticals, Inc. BPAX
We caught this stock at its 52-wk low. It was as low as .38 following our alert. 1.23 was the subsequent high, making for a 224% gainer.
BPAX had some significant news out this morning, outlining the favorable conclusion of round of testing on its GVAX Prostate cancer vaccine.
LINCOLNSHIRE, Ill., Mar 05, 2012 (BUSINESS WIRE) — BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced publication of results from a Phase I dose escalation clinical study that show its GVAX Prostate cancer vaccine in treating metastatic castration-resistant prostate cancer patients (mCRPC) in combination with ipilimumab (Ipi; Yervoy; BMS), resulted in 53 percent of patients achieving at least stable disease, with two patients showing clear regression of metastases. In addition, 23 percent of patients in the higher dose cohorts had confirmed partial PSA (prostate specific antigen) responses of greater than 50 percent from baseline.
Today’s Extended Watchlist: